(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 199.71% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.3%.
Oculis Holding Ag's revenue in 2024 is $1,003,409.On average, 4 Wall Street analysts forecast OCS's revenue for 2024 to be $37,089,501, with the lowest OCS revenue forecast at $32,984,735, and the highest OCS revenue forecast at $41,047,670. On average, 3 Wall Street analysts forecast OCS's revenue for 2025 to be $693,522,368, with the lowest OCS revenue forecast at $65,236,475, and the highest OCS revenue forecast at $1,731,332,064.
In 2026, OCS is forecast to generate $914,263,541 in revenue, with the lowest revenue forecast at $685,715,981 and the highest revenue forecast at $1,107,187,588.